

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(D)**  
**of the Securities Exchange Act of 1934**

**July 18, 2023**  
**Date of report (Date of earliest event reported)**

**MEI Pharma, Inc.**  
**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction  
of incorporation)**

**000-50484**  
**(Commission  
File Number)**

**51-0407811**  
**(IRS Employer  
Identification No.)**

**11455 El Camino Real, Suite 250**  
**San Diego, California**  
**(Address of principal executive offices)**

**92130**  
**(Zip Code)**

**Registrant's telephone number, including area code (858) 369-7100**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of Each Class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
Common stock, \$0.00000002 par value	MEIP	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 8.01. Other Events.**

On July 18, 2023, MEI Pharma, Inc. (the “Company” or “MEI”) delivered a letter dated July 17, 2023 (the “Response Letter”) to Anson Advisors Inc. and Cable Car Capital LLC (the “Requesting Stockholders”) responding to their record date request letter dated July 17, 2023, in which the Requesting Stockholders stated that they intend to commence a consent solicitation (the “Consent Solicitation”).

Also, on July 18, 2023, the Company issued a press release with a statement in response to the Consent Solicitation launched by the Requesting Stockholders on July 17, 2023.

The Response Letter and the press release are included herein as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.

---

***Important Information about the Merger and Where to Find It***

This communication relates to a proposed transaction between Infinity and the Company. In connection with the proposed merger, the Company filed with the SEC a registration statement on Form S-4 that includes a joint proxy statement of the Company and Infinity (the “Joint Proxy Statement/Prospectus”) that also constitutes a prospectus of the Company. The registration statement on Form S-4 was declared effective by the SEC on June 6, 2023. The Company and Infinity have each filed and mailed the Joint Proxy Statement/Prospectus to their respective stockholders. **INVESTORS AND THE COMPANY’S AND INFINITY’S RESPECTIVE STOCKHOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS IN ITS ENTIRETY AND ANY OTHER DOCUMENTS FILED BY EACH OF THE COMPANY AND INFINITY WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER AND THE PARTIES TO THE PROPOSED MERGER.** Investors and stockholders may obtain a free copy of the Joint Proxy Statement/Prospectus and other documents containing important information about the Company and Infinity from the SEC’s website at [www.sec.gov](http://www.sec.gov). The Company and Infinity make available free of charge at [www.meipharma.com](http://www.meipharma.com) and [www.infi.com](http://www.infi.com), respectively (in the “Investors” and “Investors/Media” sections, respectively), copies of materials they file with, or furnish to, the SEC.

***Participants in the Solicitation***

The Company, Infinity and their respective directors, executive officers and certain employees and other persons may be deemed to be participants in the solicitation of proxies from the stockholders of the Company and Infinity in connection with the proposed merger. Securityholders may obtain information regarding the names, affiliations and interests of the Company’s and Infinity’s directors and executive officers in the Joint Proxy Statement/Prospectus which may be obtained free of charge from the SEC’s website at [www.sec.gov](http://www.sec.gov), the Company’s investor website at <https://www.meipharma.com/investors> and Infinity’s investor website at <https://investors.infi.com/>.

***No Offer or Solicitation***

This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

### **Cautionary Statement Regarding Forward-Looking Statements**

Certain statements contained in this filing may be considered forward-looking statements within the meaning of the federal securities law. Such statements are based upon current plans, estimates and expectations of the management of the Company and Infinity that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as “anticipate,” “expect,” “project,” “intend,” “believe,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “forecast,” “guidance,” “predict,” “possible,” “potential,” “pursue,” “likely,” and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. All statements, other than historical facts, including statements regarding: the expected timing of the closing of the proposed merger; the ability of the parties to complete the proposed merger considering the various closing conditions; the expected benefits of the proposed merger, including estimations of anticipated cost savings and cash runway; the competitive ability and position of the combined company; the potential, safety, efficacy, and regulatory and clinical progress of the combined company’s product candidates, including the anticipated timing for initiation of clinical trials and release of clinical trial data and the expectations surrounding potential regulatory submissions, approvals and timing thereof; the sufficiency of the combined company’s cash, cash equivalents and short-term investments to fund operations; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from the Company’s and Infinity’s plans, estimates or expectations could include, but are not limited to: (i) the risk that the proposed merger may not be completed in a timely manner or at all, which may adversely affect the Company’s and Infinity’s businesses and the price of their respective securities; (ii) uncertainties as to the timing of the consummation of the proposed merger and the potential failure to satisfy the conditions to the consummation of the proposed merger, including obtaining stockholder and regulatory approvals; (iii) the proposed merger may involve unexpected costs, liabilities or delays; (iv) the effect of the announcement, pendency or completion of the proposed merger on the ability of the Company or Infinity to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom the Company or Infinity does business, or on the Company’s or Infinity’s operating results and business generally; (v) the Company’s or Infinity’s respective businesses may suffer as a result of uncertainty surrounding the proposed merger and disruption of management’s attention due to the proposed merger; (vi) the outcome of any legal proceedings related to the proposed merger or otherwise, or the impact of the proposed merger thereupon; (vii) the Company or Infinity may be adversely affected by other economic, business, and/or competitive factors; (viii) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement and the proposed merger; (ix) restrictions during the pendency of the proposed merger that may impact the Company’s or Infinity’s ability to pursue certain business opportunities or strategic transactions; (x) the risk that the Company or Infinity may be unable to obtain governmental and regulatory approvals required for the proposed merger, or that required governmental and regulatory approvals may delay the consummation of the proposed merger or result in the imposition of conditions that could reduce the anticipated benefits from the proposed merger or cause the parties to abandon the proposed merger; (xi) risks that the anticipated benefits of the proposed merger or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; (xii) the impact of legislative, regulatory, economic, competitive and technological changes; (xiii) risks relating to the value of the Company shares to be issued in the proposed merger; (xiv) the risk that integration of the proposed merger post-closing may not occur as anticipated or the combined company may not be able to achieve the benefits expected from the proposed merger, as well as the risk of potential delays, challenges and expenses associated with integrating the combined company’s existing businesses; (xv) exposure to inflation, currency rate and interest rate fluctuations, as well as fluctuations in the market price of the Company’s and Infinity’s traded securities; (xvi) the impact of the COVID-19 pandemic on the Company’s and Infinity’s industry and individual companies, including on counterparties, the supply chain, the execution of clinical development programs, access to financing and the allocation of government resources; (xvii) final data from pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; (xviii) costs and delays in the development and/or U.S. Food and Drug Administration (“FDA”) approval, or the failure to obtain such approval, of the combined company’s product candidates; (xix) regulatory authorities may not agree with the design or results of clinical studies and as a result future clinical studies may be subject to holds; (xx) uncertainties or differences in interpretation in clinical trial results; (xxi) the combined company’s inability to maintain or enter into, and the risks resulting from dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any product candidates; and (xxii) the ability of the Company or Infinity to protect and enforce intellectual property rights; and (xxiii) the unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as the Company’s and Infinity’s response to any of the aforementioned factors. Additional factors that may affect the future results of the Company and Infinity are set forth in their respective filings with the United States Securities and Exchange Commission (the “SEC”), including the section entitled “Risk Factors” in the Registration Statement on Form S-4 that was declared effective by the SEC on June 6, 2023 and each of the Company’s and Infinity’s most recently filed Annual Reports on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, which are available on the SEC’s website at [www.sec.gov](http://www.sec.gov). See in particular the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2022 in Part I, Item 1A, “Risk Factors,” and Infinity’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, in Part I, Item 1A, “Risk Factors.” The risks and uncertainties described above and in the SEC filings cited above are not exclusive and further information concerning the Company and Infinity and their respective businesses, including factors that potentially could materially affect their respective businesses, financial conditions or operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Any such forward-looking statements represent management’s reasonable estimates and beliefs as of the date of this filing. While the Company and Infinity may elect to update such forward-looking statements at some point in the future, they disclaim any obligation to do so, other than as may be required by law, even if subsequent events cause their views to change.

This Form 8-K contains hyperlinks to information that is not deemed to be incorporated by reference.

---

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">Response Letter of the Company dated July 17, 2023</a>
99.2	<a href="#">Press Release of the Company dated July 18, 2023</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MEI PHARMA, INC.**

Date: July 18, 2023

By: /s/ David M. Urso  
David M. Urso  
Chief Executive Officer



July 17, 2023

Cable Car Capital LLC  
601 California Street, Suite 1151  
San Francisco, CA 94108  
Attention: Jacob Ma-Weaver, Managing Member

Anson Advisors, Inc.  
155 University Avenue, Suite 207  
Toronto, ON, Canada, M5H 3B7  
Attention: Moez Kassam, Director

Dear Messrs. Ma-Weaver and Kassam:

I am in receipt of your letter dated July 17, 2023 ("Record Date Request Letter"). The Record Date Request Letter states that the Requesting Stockholders (as defined in the Record Date Request Letter) intend to commence a consent solicitation to: (i) remove all members of the Board without cause ("Removal Proposal") and (ii) repeal any amendments to the Bylaws (as defined in the Record Date Request Letter) enacted since February 23, 2023 ("Bylaw Proposal").

The Removal Proposal is invalid under Delaware law, and therefore the approval thereof is not a proper matter for stockholder action either at a stockholder meeting or by written consent. *See* 8 Del. C. § 228( a) (permitting stockholders to take, by consent in lieu of a meeting, "any action *which may be taken* at any ... meeting of stockholders") (emphasis added). Under Article TENTH of the Amended and Restated Certificate of Incorporation of the Company ("Charter"), the Company has a classified board. As a result, "*unless the certificate of incorporation otherwise provides,*" directors may only be removed "*for cause.*" 8 Del. C. § 141(k) (emphasis added). The Charter does not so otherwise provide. Moreover, given the statutory text, this rule is "not subject to modification by bylaw." *Jones Apparel Group, Inc. v. Maxwell Shoe Co., Inc.*, 883 A.2d 837, 848 (Del. Ch. 2004). Therefore, the Removal Proposal is invalid, notwithstanding any bylaw provision or disclosure to the contrary. *See also* 8 Del. C. § 109(b) ("The bylaws may contain any provision, *not inconsistent with law or with the certificate of incorporation,* relating to the business of the corporation, the conduct of its affairs, and its rights or powers or the rights or powers of its stockholders, directors, officers or employees.") (emphasis added).

With respect to the Bylaw Proposal, the Bylaws have not been amended since February 23, 2023, and the Board has no current intent to amend the Bylaws. In addition, we note that, in your consent solicitation statement, you state that you are asking stockholders to consent to the adoption of the Bylaw Proposal "to ensure that the incumbent Board does not limit the effect" of the removal of directors. As stated above, however, the Removal Proposal is invalid.

11455EI Camino Real, Suite 250, San Diego, CA 92130



For these reasons, and after consultation with the Board, I inform you that the Board does not intend to set a record date as requested in the Record Date Request Letter. If you nonetheless persist in pursuing this invalid proposal, the Bylaws provide default record dates for action by written consent. However, we urge you not to so pursue your solicitation for these clearly invalid and unnecessary proposals that, if pursued, will result in the unnecessary expenditure of corporate time and resources, and we reserve all rights to contest the validity of any such solicitation or the actions purportedly taken in connection therewith.

Sincerely,

/s/ Brian G. Drazba  
Brian G. Drazba  
Secretary and Chief Financial Officer

CC (via email):

Olshan Frome Wolosky LLP  
1325 Avenue of the Americas  
New York, NY 10019  
Attention: Andrew Freedman ([afreedman@olshanlaw.com](mailto:afreedman@olshanlaw.com))

Morgan, Lewis & Bockius LLP  
101 Park Avenue  
New York, NY 10178  
Attention: Steven A. Navarro ([steven.navarro@morganlewis.com](mailto:steven.navarro@morganlewis.com)) and Robert W. Dickey ([robert.dickey@morganlewis.com](mailto:robert.dickey@morganlewis.com))

Morris, Nichols, Arsht & Tunnell LLP  
1201 N. Market Street  
P.O. Box 1347  
Wilmington, DE 19899-1347  
Attention: S. Mark Hurd ([shurd@morrisnichols.com](mailto:shurd@morrisnichols.com)) & Eric Klinger-Wilensky ([ekwilensky@morrisnichols.com](mailto:ekwilensky@morrisnichols.com))

11455El Camino Real, Suite 250, San Diego, CA 92130





### MEI Pharma Responds to Anson and Cable Car

SAN DIEGO, July 18, 2023 – MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today issued the following statement in response to the Consent Solicitation launched by Anson Advisors Inc. and Cable Car Capital LLC on July 17, 2023:

Anson and Cable Car have launched a process, called a consent solicitation, in an attempt to take control of the Company by removing MEI’s directors. The consent solicitation further seeks to have MEI repeal any amendment to our bylaws since February 22, 2023 and prevent any future amendment prior to completion of the consent solicitation.

As we noted in our direct response back to Anson and Cable Car, MEI is incorporated in Delaware and their attempt to remove our Board of Directors without cause is not allowed under Delaware law. Moreover, the MEI Board has not made or proposed any modification of the bylaws to date, nor does it have any current intention to do so. **We encourage our shareholders not to be misled by Anson and Cable Car’s latest unconstructive attempts to takeover the Company.**

The MEI Board and management team are committed to creating shareholder value, and will take actions that they believe are in the best interest of all of the Company’s shareholders.

Our Board reiterates its recommendation that shareholders vote FOR our pending transaction with Infinity Pharmaceuticals, Inc (“Infinity”). Independent leading proxy advisory firms ISS and Glass Lewis both recognize the strategic benefits of the transaction and also recommend shareholders vote FOR the Infinity transaction.

The Company’s response to the consent solicitation from Anson and Cable Car was filed on Form 8-K with the U.S. Securities and Exchange Commission on July 18, 2023.

Stifel is serving as financial advisor to MEI Pharma and Morgan Lewis is serving as legal counsel.



Shareholders who have questions or need assistance voting your shares, please contact Alliance Advisors, MEI's proxy solicitor:

Alliance Advisors, LLC  
200 Broadacres Drive, 3<sup>rd</sup> Floor  
Bloomfield, NJ 07003  
+1 (888) 511-2635  
Email: MEIP@allianceadvisors.com

Stifel is serving as financial advisor to MEI Pharma and Morgan Lewis is serving as legal counsel.

### **About MEI Pharma**

MEI Pharma, Inc. (Nasdaq: MEIP) is a pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's portfolio of drug candidates includes clinical stage candidates with differentiated mechanisms of action intended to address unmet medical needs and deliver improved benefit to patients, either as standalone treatments or in combination with other therapeutic options. For more information, please visit [www.meipharma.com](http://www.meipharma.com). Follow us on Twitter @MEI\_Pharma and on LinkedIn.

### **Important Information about the Merger and Where to Find It**

This communication relates to a proposed transaction between Infinity and the Company. In connection with the proposed merger, the Company filed with the United States Securities and Exchange Commission (the "SEC") a registration statement on Form S-4 that includes a joint proxy statement of the Company and Infinity (the "Joint Proxy Statement/Prospectus") that also constitutes a prospectus of the Company. The registration statement on Form S-4 was declared effective by the SEC on June 6, 2023. The Company and Infinity have each filed and mailed the Joint Proxy Statement/Prospectus to their respective shareholders. **INVESTORS AND THE COMPANY'S AND INFINITY'S RESPECTIVE SHAREHOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS IN ITS ENTIRETY AND ANY OTHER DOCUMENTS FILED BY EACH OF THE COMPANY AND INFINITY WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER AND THE PARTIES TO THE PROPOSED MERGER.** Investors and shareholders may obtain a free copy of the Joint Proxy Statement/Prospectus and other documents containing important information about the Company and Infinity from the SEC's website at [www.sec.gov](http://www.sec.gov). The Company and Infinity make available free of charge at [www.meipharma.com](http://www.meipharma.com) and [www.infi.com](http://www.infi.com), respectively (in the "Investors" and "Investors/Media" sections, respectively), copies of materials they file with, or furnish to, the SEC.

**Participants in the Solicitation**

The Company, Infinity and their respective directors, executive officers and certain employees and other persons may be deemed to be participants in the solicitation of proxies from the shareholders of the Company and Infinity in connection with the proposed merger. Securityholders may obtain information regarding the names, affiliations and interests of the Company's and Infinity's directors and executive officers in the Joint Proxy Statement/Prospectus which may be obtained free of charge from the SEC's website at [www.sec.gov](http://www.sec.gov), the Company's investor website at <https://www.meipharma.com/investors> and Infinity's investor website at <https://investors.infi.com/>.

**No Offer or Solicitation**

This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

**Cautionary Statement Regarding Forward-Looking Statements**

Certain statements contained in this communication may be considered forward-looking statements within the meaning of the federal securities law. Such statements are based upon current plans, estimates and expectations of the management of the Company and Infinity that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as "anticipate," "expect," "project," "intend," "believe," "may," "will," "should," "plan," "could," "continue," "target," "contemplate," "estimate," "forecast," "guidance," "predict," "possible," "potential," "pursue," "likely," and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. All statements, other than historical facts, including statements regarding: the expected timing of the closing of the proposed merger; the ability of the parties to complete the proposed merger considering the various closing conditions; the expected benefits of the proposed merger, including estimations of anticipated cost savings and cash runway; the competitive ability and position of the combined company; the potential, safety, efficacy, and regulatory and clinical progress of the combined company's product candidates, including the anticipated timing for initiation of clinical trials and release of clinical trial data and the expectations surrounding potential regulatory submissions, approvals and timing thereof; the sufficiency of the combined company's cash, cash equivalents and short-term investments to fund operations; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from the Company's and Infinity's plans, estimates or expectations could include, but are not limited to: (i) the risk that the proposed merger may not be completed in a timely manner or at all, which may adversely

affect the Company's and Infinity's businesses and the price of their respective securities; (ii) uncertainties as to the timing of the consummation of the proposed merger and the potential failure to satisfy the conditions to the consummation of the proposed merger, including obtaining shareholder and regulatory approvals; (iii) the proposed merger may involve unexpected costs, liabilities or delays; (iv) the effect of the announcement, pendency or completion of the proposed merger on the ability of the Company or Infinity to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom the Company or Infinity does business, or on the Company's or Infinity's operating results and business generally; (v) the Company's or Infinity's respective businesses may suffer as a result of uncertainty surrounding the proposed merger and disruption of management's attention due to the proposed merger; (vi) the outcome of any legal proceedings related to the proposed merger or otherwise, or the impact of the proposed merger thereupon; (vii) the Company or Infinity may be adversely affected by other economic, business, and/or competitive factors; (viii) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement and the proposed merger; (ix) restrictions during the pendency of the proposed merger that may impact the Company's or Infinity's ability to pursue certain business opportunities or strategic transactions; (x) the risk that the Company or Infinity may be unable to obtain governmental and regulatory approvals required for the proposed merger, or that required governmental and regulatory approvals may delay the consummation of the proposed merger or result in the imposition of conditions that could reduce the anticipated benefits from the proposed merger or cause the parties to abandon the proposed merger; (xi) risks that the anticipated benefits of the proposed merger or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; (xii) the impact of legislative, regulatory, economic, competitive and technological changes; (xiii) risks relating to the value of the Company shares to be issued in the proposed merger; (xiv) the risk that integration of the proposed merger post-closing may not occur as anticipated or the combined company may not be able to achieve the benefits expected from the proposed merger, as well as the risk of potential delays, challenges and expenses associated with integrating the combined company's existing businesses; (xv) exposure to inflation, currency rate and interest rate fluctuations, as well as fluctuations in the market price of the Company's and Infinity's traded securities; (xvi) the impact of the COVID-19 pandemic on the Company's and Infinity's industry and individual companies, including on counterparties, the supply chain, the execution of clinical development programs, access to financing and the allocation of government resources; (xvii) final data from pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; (xviii) costs and delays in the development and/or U.S. Food and Drug Administration ("FDA") approval, or the failure to obtain such approval, of the combined company's product candidates; (xix) regulatory authorities may not agree with the design or results of clinical studies and as a result future clinical studies may be subject to holds; (xx) uncertainties or differences in interpretation in clinical trial results; (xxi) the combined company's inability to maintain or enter into, and the risks resulting from dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any product candidates; and (xxii) the ability of the Company or Infinity to protect and enforce



intellectual property rights; and (xxiii) the unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as the Company's and Infinity's response to any of the aforementioned factors. Additional factors that may affect the future results of the Company and Infinity are set forth in their respective filings with the SEC, including the section entitled "Risk Factors" in the Registration Statement on Form S-4 that was declared effective by the SEC on June 6, 2023 and each of the Company's and Infinity's most recently filed Annual Reports on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, which are available on the SEC's website at [www.sec.gov](http://www.sec.gov). See in particular the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2022 in Part I, Item 1A, "Risk Factors," and Infinity's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, in Part I, Item 1A, "Risk Factors." The risks and uncertainties described above and in the SEC filings cited above are not exclusive and further information concerning the Company and Infinity and their respective businesses, including factors that potentially could materially affect their respective businesses, financial conditions or operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Any such forward-looking statements represent management's reasonable estimates and beliefs as of the date of this filing. While the Company and Infinity may elect to update such forward-looking statements at some point in the future, they disclaim any obligation to do so, other than as may be required by law, even if subsequent events cause their views to change.

#### **Contacts**

David A. Walsey  
858-369-7104  
[investor@meipharma.com](mailto:investor@meipharma.com)

Joele Frank, Wilkinson Brimmer Katcher  
Dan Katcher / Aaron Palash  
212-355-4449  
[MEIP-jf@joelefrank.com](mailto:MEIP-jf@joelefrank.com)